Venous thromboembolism drugs to experience robust growth by 2019

NewsGuard 100/100 Score

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and widespread uptake of novel oral anticoagulants, the combined markets for drugs used in the treatment and prophylaxis of venous thromboembolism will experience robust growth, increasing from $2.9 billion in 2009 to more than $5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Venous Thromboembolism reveal that, in 2009, the leading therapies for VTE treatment/secondary prophylaxis and primary prophylaxis were low-molecular-weight heparins (LMWHs) and vitamin K antagonists (VKAs). The hold that these therapies have on the market will be severely reduced following the introduction and deep market penetration of novel therapies that offer significant benefits over currently available agents. Sales of the leading LMWH, Sanofi-Aventis's Lovenox, will also be affected by the launch of generic versions of the drug, beginning in 2010.

The Pharmacor 2010 findings also reveal that the high unmet need for a novel oral anticoagulant for the acute treatment and long-term secondary prophylaxis of VTE will fuel stronger rates of growth in this market compared with the venous thromboembolism primary prophylaxis market.

"The emerging oral anticoagulants will revolutionize current medical practice for preventing and treating VTE – the broad clinical development program of Bayer/Ortho-McNeil's Xarelto, coupled with its impressive performance in Phase III studies, will enable it to emerge as the sales leading oral anticoagulant in the VTE market," said Decision Resources Analyst Matthew Killeen, Ph.D. "Nevertheless, Xarelto will face strong competition from rival oral agents including Bristol-Myers Squibb/Pfizer's apixaban and Boehringer Ingelheim's Pradaxa, both of which are in late-stage development."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Anti-obesity medications slash heart disease risk in obese patients, study finds